← Human Trials & Peer-Reviewed Studies
Superiority of a vitamin B12-barrier cream compared with standard glycerol-petrolatum-based emollient cream in the treatment of atopic dermatitis: A randomized, left-to-right comparative trial
Plain-language guide to PMID 28677237 (2017): single-blind randomized controlled trial study of Cyanocobalamin (Vitamin B12) in 22 patients.
Key Facts
- PMID
- 28677237
- Journal
- Dermatologic therapy
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Nistico SP et al. (7 authors)
- DOI
- 10.1111/dth.12523
What This Study Did, in Plain Language
What Was Tested
Researchers studied Cyanocobalamin (Vitamin B12) in this randomized controlled trial publication.
Atopic dermatitis (AD) is a result of complex genetic, epigenetic, environmental, and immunological interactions with an overlapping epidermal barrier defect.
The study was conducted as a on one hemi-body randomized, controlled, single-blind, intra-patient left-to-right comparative trial by patients with clinical diagnosis of mild AD measured with total SCORAD index over 4 months.
Who Took Part
The study group was 22 patients.
PubMed tags the participants as both men and women.
How the Study Was Run
The design is described as randomized and single-blind.
Random assignment meant chance, not the researchers, decided who got Cyanocobalamin (Vitamin B12) and who got the comparison, which limits bias.
Only one side, usually the patients, was kept unaware of whether Cyanocobalamin (Vitamin B12) was given.
A time span of 4 months appears in the methods.
What Was Measured
The study was conducted as a on one hemi-body randomized, controlled, single-blind, intra-patient left-to-right comparative trial by patients with clinical diagnosis of mild AD measured with total SCORAD index over 4 months.
Topics PubMed links to this paper include Administration, Cutaneous, Dermatitis, Atopic, Dermatologic Agents, Emollients, Glycerol, Petrolatum and Statistics, Nonparametric.
Author keywords: atopic dermatitis, hydration and skin barrier.
What This Means in Plain Language
The paper is a randomized and single-blind study of Cyanocobalamin (Vitamin B12) in 22 patients over 4 months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2017 (Dermatologic therapy), a journal based in United States.
More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.
Our Notes on the Compound
Cyanocobalamin (Vitamin B12): A synthetic form of vitamin B12 (cobalamin), an essential nutrient for DNA synthesis, red blood cell formation and neurological function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.